Apellis Pharmaceuticals
APLS
APLS
254 hedge funds and large institutions have $4.34B invested in Apellis Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 46 funds opening new positions, 126 increasing their positions, 64 reducing their positions, and 106 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
less funds holding
Funds holding: →
33% less funds holding in top 10
Funds holding in top 10: 15 → 10 (-5)
55% less capital invested
Capital invested by funds: $9.71B → $4.34B (-$5.37B)
57% less first-time investments, than exits
New positions opened: 46 | Existing positions closed: 106
Holders
254
Holding in Top 10
10
Calls
$373M
Puts
$139M
Top Buyers
| 1 | +$323M | |
| 2 | +$207M | |
| 3 | +$78.7M | |
| 4 |
Jennison Associates
New York
|
+$59.8M |
| 5 |
State Street
Boston,
Massachusetts
|
+$36.3M |
Top Sellers
| 1 | -$201M | |
| 2 | -$113M | |
| 3 | -$97.3M | |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$74.8M |
| 5 |
PA
Perceptive Advisors
New York
|
-$74M |